PHA’s Research Program
“PHA’s research program funds some of the best science and the brightest people in the nation.”
– Dr. John Newman, Vanderbilt University Medical Center
PHA’s Research Program has committed approximately $8 million to support cutting-edge research focused on pulmonary hypertension. PHA has been able to leverage such substantial funding through partnerships with the National Heart, Lung, and Blood Institute (NHLBI) and the Foundation of the American Thoracic Society (ATS).
PHA’s grants to promising researchers cultivate new leaders in the field by supporting their interest in PH research and providing them with opportunities to work with mentors and learn new skills. Researchers supported by PHA are looking for new methods for early detection, new treatments to prevent the onset of PH and ultimately a cure for this terrible illness.
Offering five active, independently reviewed cutting-edge research programs each year, PHA has awarded grants to more than 70 researchers since the inception of the program.
The Aldrighetti Research Award for Young Investigators
This award, named for PHA’s first President & CEO, Rino Aldrighetti, was established and sponsorship support provided by Actelion Pharmaceuticals US, Inc. Established at PHA’s 12th International PH Conference and Scientific Sessions in June 2016, the program supports the careers of young investigators who are likely to make a strong and sustained impact in PAH research.
PHA/ATS Research Fellowship in Pulmonary Arterial Hypertension
Through a co-funded partnership, the PHA/ATS Research Fellowship in Pulmonary Arterial Hypertension supports junior faculty-level researchers. PHA supports researchers covering very different aspects of pulmonary hypertension (PH) ranging from the role that genetics plays in the occurrence of PH to how hypoxia affects newborns with PH and much more.
Robyn J. Barst, MD Pediatric PH Research and Mentoring Program
Grants from the Barst Fund provide support for one-year mentorship awards for young U.S.-based physician-researchers in the field of pediatric pulmonary hypertension (PH), holding an MD, DO or equivalent degree. Grantees will be expected to engage with an experienced mentor who is able to provide oversight and training in pediatric PH treatment, management and research. In addition, grantees will complete a proof of concept research project. These novel projects, combined with experienced mentor/mentee collaboration, are expected to significantly advance the young researcher’s knowledge, and ultimately, the field of pediatric PH.
PHA Proof of Concept Research Grants
This program offers support for new research projects that should result in the development of data enabling the investigator to apply for a larger, hypotheses-driven research project. This program supports new research projects that are in the early exploratory and developmental stages and have the potential to lead to advances in the scientific understanding of pulmonary hypertension. Proposed projects result in preliminary data that will enable the investigator to apply for support for a larger, hypotheses-driven research project.
PHA/NHLBI Mentored Clinical Scientist Award (K08)/Mentored Patient-Oriented Research Career Development Award (K23)
Through a career development award partnership with the National Heart, Lung, and Blood Institute (NHLBI), the Pulmonary Hypertension Association is pleased to provide supplemental funding to individuals who receive an NHLBI Mentored Clinical Scientist Research Career Development Award (K08) or a Mentored Patient-Oriented Research Career Development Award (K23) for research on pulmonary hypertension. The K23 award is focused on patient oriented research where clinicians interact directly with patients in their studies. The K08 award provides support to researchers through supervised research career development in the fields of biomedical and behavioral research, including translational research but whose studies do not include direct interaction with patients.
A partnership with the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health that supports a comprehensive, deep-phenotyping across the current World Health Organization (WHO) classifications of pulmonary hypertension (Groups 1 through 5).